Paraoxonases role in the prevention of cardiovascular diseases

BioFactors

Volumn 35, Issue 1, 2009, Pages 98-104

  Rosenblat, Mira ^a   Aviram, Michael ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antioxidants; Atherosclerosis; Macrophages; Oxidative stress; Paraoxonase 1; Paraoxonase 2

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; BETA CAROTENE; HIGH DENSITY LIPOPROTEIN; LYCOPENE; POLYPHENOL; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN; PON2 PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; ENZYME INACTIVATION; GENE EXPRESSION; GLYCYRRHIZA; HUMAN; NONHUMAN; OXIDATIVE STRESS; POMEGRANATE; PRIORITY JOURNAL; RED WINE; REVIEW; RISK ASSESSMENT; ANIMAL; BIOLOGICAL MODEL; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALIA; GLYCYRRHIZA; LYTHRACEAE;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; MODELS, BIOLOGICAL;

EID: 65549138006     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.16     Document Type: Review

References (50)

1. Tsimikas, S. (2008) In vivo markers of oxidative stress and therapeutic interventions. Am. J. Cardiol. 101, 34D-42D.
2. Renard, C. and Van Obberghen, E. (2006) Role of diabetes in atherosclerosis pathogenesis. What have we learned from animal models?Diabetes Metab. 32, 15-29.
3. Dickhout, J. G., Basseri, S., and Austin, R. C. (2008) Macrophage function and its impact on atherosclerotic lesion composition, progression, and stability: the good, the bad, and the ugly. Arterioscler. Thromb. Vasc. Biol. 28, 1413-1415.
4. Aviram, M. and Rosenblat, M. (2003) Oxidative stress in cardiovascular disease: role of oxidized lipoproteins in macrophage foam cell formation and atherosclerosis. In Redox-Genome Interactions in Health and Disease. Chapter 25, pp. 57-90, Dekker, New York.
5. Fuhrman, B., Partoush, A., Volkova, N., and Aviram, M. (2008) Ox-LDL induces monocyte-to macrophage differentiation in vivo: possible role for the macrophage colony stimulating factor receptor (M-CSF-R). Atherosclerosis 196, 598-607.
6. Fuhrman, B., Volkova, N., and Aviram, M. (2002) Oxidative stress increases the expression of the CD36 scavenger receptors and the cellular uptake of oxidized LDL in macrophages from atherosclerotic mice: protective role of antioxidants and paraoxonase. Atherosclerosis 161, 307-316.
7. Aviram, M., Kaplan, M., Rosenblat, M., and Fuhrman, B. (2005) Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handbook Exp. Pharmacol. 170, 263-300.
8. Fuhrman, B., Lavy, A., and Aviram, M. (1995) Consumption of red wine with meals reduces the susceptibility of human plasma and LDL to undergo lipid peroxidation. Am. J. Clin. Nutr. 61, 549-554.
9. Naissides, M., Pal, S., Mamo, J. C., James, A. P., and Dhaliwal, S. (2006) The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. Atherosclerosis 185, 438-445. (Pubitemid 43306762)
10. Aviram, M., Rosenblat, M., Gaitini, D., Nitecki, S., Hoffman, A., Dornfeld, L., Volkova, N., Presser, D., Attias, J., Liker, H., and Hayek, T. (2004) Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. 23, 423-433.
11. Sumner, M. D., Elliott-Eller, M., Weidner, G., Daubenmier, J. J., Chew, M. H., Marlin, R., Raisin, C. J., and Ornish, D. (2005) Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Am. J. Cardiol. 96, 810-814.
12. Rosenblat, M., Hayek, T., and Aviram, M. (2006) Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 188, 68-76.
13. Lind, L., Andersson, J., Rönn, M., Gustavsson, T., Holdfelt, P., Hulthe, J., Elmgren, A., Zilmer, K., and Zilmer, M. (2008) Brachial artery intimamedia thickness and echogenicity in relation to lipids and markers of oxidative stress in elderly subjects: the prospective investigation of the vasculature in Uppsala Seniors (PIVUS) Study. Lipids 43, 133-141.
14. Rosenblat, M., Volkova, N., Coleman, R., and Aviram, M. (2007) Anti-oxidant and anti-atherogenic properties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice. Atherosclerosis 195, E61-E68.
15. Ramakrishna, V. and Jailkhani, R. (2008) Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 45, 41-46.
16. Moskaug, J. Q., Carlsen, H., Myhrstad, M. C., and Blomhoff, R. (2005) Polyphenols and glutathione synthesis regulation. Am. J. Clin. Nutr. 81, 277S- 283S.
17. Rozenberg, O., Howell, A., and Aviram, M. (2006) Pomegranate juice sugar fraction reduces macrophage oxidative stress, whereas white grape juice sugar fraction increases it. Atherosclerosis 188, 68-76.
18. Ng, C. J., Shih, D. M., Hama, S. Y., Villa, N., Navab, M., and Reddy, S. T. (2005) The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med. 38, 153-163.
19. Gaidukov, L. and Tawfik, D. S. (2005) High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry 44, 11843-11854.
20. Ng, C. J., Wadleigh, D. J., Gangopadhyay, A., Hama, S., Grijalva, V. R., Navab, M., Fogelman, A. M., and Reddy, S. T. (2001) Paraoxonase-2 is an ubiquitously expressed protein with antioxidant properties, and is capable of preventing cell-mediated oxidative modification of low-density lipoprotein. J. Biol. Chem. 276, 44444-44449.
21. Rosenblat, M., Draganov, D., Watson, C. E., Bisgaier, C. L., La Du, B. N., and Aviram, M. (2003) Mouse macrophage paraoxonase 2 (PON2) activity is increased whereas cellular PON3 activity is decreased under oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 468-474.
22. Reddy, S. T., Devarajan, A., Bourquard, N., Shih, D. M., and Fogelman, A. M. (2008) Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Curr. Opin. Lipidol. 19, 405-408.
23. Fuhrman, B., Volkova, N., and Aviram, M. (2005) Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Atherosclerosis 180, 55-61.
24. Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. H., Hill, E., Roberts, C., Durrington, P. N., and Mackness, M. I. (2001) Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21, 1451-1457.
25. Harangi, M., Seres, I., Magyar, M. T., Csipo, I., Sipka, S., Valikovics, A., Csiba, L., Bereczki, D., and Paragh, G. (2008) Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery diseases. Cerebrovasc. Dis. 25, 122-128.
26. Efrat, M., Rosenblat, M., Mahmood, S., Vaya, J., and Aviram, M. (2008) Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies. Atherosclerosis, in press.
27. Aviram, M., Rosenblat, M., Bisgaier, C. L., Newton, R. S., Primo-Parmo, S. L., and La Du, B. N. (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101, 1581-1590.
28. Aviram, M. and Rosenblat, M. (2004) Paraoxonases 1, 2 and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Chem. 37, 1304-1316.
29. Aviram, M., Hardak, E., Vaya, J., Mahmood, S., Milo, S., Hoffman, A., Billicke, S., Draganov, D., and Rosenblat, M. (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101, 2510-2517.
30. Guns, P. J., Van Assche, T., Verreth, W., Fransen, P., Mackness, B., Mackness, M., Holvoet, P., and Bult, H. (2008) Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Br. J. Pharmacol. 153, 508-516.
31. Rosenblat, M., Oren, R., and Aviram, M. (2006) Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL. Biochem. Biophys. Res. Commun. 344, 1271-1277.
32. Rosenblat, M., Gaidukov, L., Khersonsky, O., Rosenblat, M., Vaya, J., Oren, R., Tawfik, D. S., and Aviram, M. (2006) The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J. Biol. Chem. 281, 7657-7665.
33. Efrat, M. and Aviram, M. (2008) Macrophage paraoxonase1 (PON1) binding sites. Biochem. Biophys. Res. Commun. 376, 105-110.
34. Letellier, C., Durou, M. R., Jouanolle, A. M., Le Gall, J. Y., Poirier, J. Y., and Ruelland, A. (2002) Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab. 28, 297-304.
35. Rosenblat, M., Karry, R., and Aviram, M. (2006) Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis 187, 74-81.
36. Mastorikou, M., Mackness, B., Liu, Y., and Mackness, M. (2008) Glycation of paraoxonase 1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet. Med. 25, 1049-1055.
37. Mastorikou, M., Mackness, M., and Mackness, B. (2006) Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 55, 3099-3103.
38. Rozenberg, O., Shiner, M., Aviram, M., and Hayek, T. (2008) Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic. Biol. Med. 44, 1951-1959.
39. Aviram, M. (2004) Introduction to the serial review on paraoxonases, oxidative stress, and cardiovascular diseases. Free Radic. Biol. Med. 37, 1301-1303.
40. Karabina, S. A., Lehner, A. N., Frank, E., Parthasarathy, S., and Santanam, N. (2005) Oxidative inactivation of paraoxonase-implications in diabetes mellitus and atherosclerosis. Biochem. Biophys. Acta. 1725, 213-221.
41. Aviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C. L., Newton, R. S., and La Du, B. N. (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26, 892-904.
42. Rozenberg, O. and Aviram, M. (2006) S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity. Biochem. Biophys. Res. Commun. 351, 492-498.
43. Rock, W., Rosenblat, M., Miller-Lotan, R., Levy, A. P., Elias, M., and Aviram, M. (2008) Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J. Agric. Food Chem. 56, 8704-8713.
44. Aviram, M., Rosenblat, M., Bisgaier, C. L., and Newton, R. S. (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138, 271-280.
45. Nguyen, S. D. and Sok, D. E. (2003) Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem. J. 375, 275-285.
46. Rosenblat, M., Hayek, T., Hussein, K., and Aviram, M. (2004) Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler. Thromb. Vasc. Biol. 24, 175-180.
47. Horke, S., Witte, I., Wilgenbus, P., KrÜger, M., Strand, D., and Förstermann, U. (2007) Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stress-induced caspase activation. Circulation 115, 2055-2064.
48. Shiner, M., Fuhrman, B., and Aviram, M. (2004) Paraoxonase 2 (PON2) expression is upregulated via a reduced nicotinamide- adenine-dinucleotide- phosphate (NADPH)- oxidase- dependent mechanism during monocytes differentiation into macrophages. Free Radic. Biol. Med. 37, 2052-2063.
49. Fuhrman, B., Khateeb, J., Shiner, M., Nitzan, O., Karry, R., Volkova, N., and Aviram, M. (2008) Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol. 28, 1361-1367.
50. Shiner, M., Fuhrman, B., and Aviram, M. (2007) Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPARgamma and AP-1 pathway activation. Atherosclerosis 195, 313-321.